Chloroquine
DrugComparison of two different dosages of chloroquine for treatment of falciparum malaria in Afghan refugee camps in Northwest Frontier Province, Pakistan
Other names: CQ
NCT Number: NCT01019408
The purpose of this study was to provide stronger evidence for extended-dose chloroquine treatment of falciparum-positive Afghan refugees in Northwest Frontier Province (NWFP), Pakistan or justification for discontinuation of the policy.
Looking for future studies?
Notify Me6 month–60 year
All sexes
Interventional
Phase 4
Adezai Basic Health Unit, Adezai, Khyber Pakhtunkhwa, Pakistan
To determine whether extended-dose chloroquine provided better cure rates and fewer recrudescences than standard chloroquine treatment among Afghan refugees, 163 falciparum patients from three Afghan refugee camps were recruited into 3-day (CQ 25mg/kg) or 5-day (CQ 40mg/kg) treatment arms and followed for up to 60 days.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Comparison of two different dosages of chloroquine for treatment of falciparum malaria in Afghan refugee camps in Northwest Frontier Province, Pakistan
Other names: CQ
Time frame: 60 days
Time frame: 28 days
Time frame: 28 days
Time frame: 28 days
London School of Hygiene and Tropical Medicine
Other
Clinical Trial of Extended-dose Chloroquine Versus Standard Chloroquine Treatment for Resistant Falciparum Malaria Among Afghan Refugees in NWFP Pakistan
Acronym: ECQNWFP
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06171113
Infections, Malaria
Cambridge, United Kingdom
View Trial DetailsNCT02014727
Infections, Malaria
Ouagadougou, Burkina Faso
View Trial DetailsNCT07027722
Antimalarials, Artemisinins
Saint-Denis, France
View Trial DetailsNCT04839900
Infections, Malaria
Chadiza, Eastern Provice, Zambia
View Trial Details